Breast Cancer Trial, Recruiting NCT05763641 Sponsor: Hospital Universitari de Bellvitge Condition: Breast Cancer
Back to Breast Cancer

Breast Cancer Trial, Recruiting

NCT05763641
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have cancer cells confirmed in their underarm (axillary) lymph nodes through a laboratory test of a cell sample
  • People who have at least 4 suspicious lymph nodes visible in their underarm area on an ultrasound scan at the time of diagnosis
  • People with an extensive form of breast cancer (T4 stage) where removal of underarm lymph nodes is recommended based on current medical guidelines (confirm with trial site)
  • People who are receiving chemotherapy before surgery (called neoadjuvant chemotherapy)

Who may not be able to join:

  • People whose imaging tests show a more advanced level of lymph node involvement known as cN3
  • People whose lymph node involvement is in the internal mammary nodes (nodes near the breastbone) rather than the underarm area, classified as N2b
  • People whose breast cancer type is classified as "Luminal A" based on molecular testing
  • People who are receiving hormone-based therapy before surgery (called neoadjuvant endocrine therapy) rather than chemotherapy
  • People who have a return of cancer in the same area (local recurrence) or cancer that has spread to other parts of the body (metastatic cancer)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: amparo Garcia-Tejedor, MDPhD, Instituto de Investigación Biomédica de Bellvitge (IDIBELL)

Phone: 0034-932607702

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Hospital Universitari de Bellvitge
Registry
ClinicalTrials.gov
Start date
1 February 2021
Est. completion
1 June 2026

Where this trial is recruiting

🇪🇸 Spain

Primary endpoints

TAD validation in locally advanced breast cancer

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov